Viking Therapeutics Presents VK2735 Trial Data in Istanbul
Viking Therapeutics presented additional data from its Phase 2 VENTURE-Oral Dosing trial evaluating the oral tablet formulation of VK2735 at the European Congress on Obesity in Istanbul. VK2735 is in development with subcutaneous and oral formulations for the potential treatment of various metabolic disorders. The poster highlighted key findings from previously reported trial data, including mean change from baseline in body weight throughout the 13-week treatment period and additional safety and tolerability data, for the Phase 2 study of orally administered VK2735. Participants receiving once-daily oral VK2735 demonstrated statistically significant, dose-dependent weight loss from baseline of up to 12.2% at 13 weeks across all dose cohorts. Compared with placebo, doses greater than15 mg demonstrated dose-dependent and progressive weight loss starting early in treatment and continuing through the 13-week treatment window, with no plateau. VK2735 was well tolerated, with the vast majority of treatment-emergent adverse events reported as mild or moderate in severity. Baseline characteristics in the ongoing Phase 3 VANQUISH-1 study of VK2735 in adults with obesity were also presented.
